# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2021

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2021-08-10
- Accepted by EDGAR: Aug 10, 2021, 14:06 ET
- Period: 2021-06-30
- Accession: 0001564590-21-042998
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459021042998/avd-10q_20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459021042998/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $134.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $250.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $82.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $153.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $52.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-01 to 2021-06-30 | $97.3m | us-gaap:GrossProfit |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | $9.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | $12.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-04-01 to 2021-06-30 | $1.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2021-01-01 to 2021-06-30 | $2.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | $3.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | $5.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | $8.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | $0.17 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | $0.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | $0.17 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | $0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 30,499,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 30,511,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$18.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 6 months, 2021-01-01 to 2021-06-30 | $1.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2021-06-30 | $19.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $373.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $735.4m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $165.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $366.1m | us-gaap:Liabilities |
| Long-term debt | at 2021-06-30 | $149.4m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2021-06-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2021-06-30 | $369.4m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 39,029 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

### MANAGEMENT OVERVIEW

### The Company’s Operations in the Context of the COVID-19 Pandemic

Since the start of the coronavirus pandemic early in 2020, the company has made sustained efforts to maintain the health and safety of the workforce while ensuring continuity of the business, which, under applicable federal guidelines (https://ww.cisa.gov) is part of the nation’s critical infrastructure (as part of the “Food and Agriculture,” “Chemical” and “Public Works and Infrastructure Support Services” sectors). In the workplace, we have designed and implemented protocols for social distancing, made provisions for the workforce to work remotely where possible, and established quarantine policies for those who present COVID-like symptoms or may have been in contact with those who have. Further, we keep current with local, state, federal and international laws and restrictions that could affect the business and provide real-time information to the workforce. We have also prepared contingency plans to permit the continued operation of our factories, in the event that there are critical staffing issues. Further, we continuously monitor supply chain, transportation, logistics and border closures and have reached out to third parties to make clear that we are continuing to operate, that we have our own policies relating to health and that we are committed to compliance with COVID-19 policies of our business partners.

As has been the case with many other employers, since the start of 2021, we have encouraged our workforce to receive vaccinations against COVID-19 through various means, including incentive programs. However, new variants, particularly the Delta variant, have engendered a resurgence of the virus in many regions particularly among the unvaccinated. In the midst of changing conditions, we have nevertheless been able to manage our business with minimal impact during the reporting period.

Looking forward, the Company is unable to predict the ultimate impact that the pandemic may have on its future financial condition, results of operations and cash flows due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers in the near term will depend on future developments, which are highly uncertain and, beyond extrapolating our experience since the start of the pandemic, cannot be predicted with certainty. The Company continues to monitor its business for adverse impacts of the pandemic, including volatility in the foreign exchange markets, demand, supply-chain disruptions in certain markets, and increased costs of employee safety, among others.

### Three Months Ended June 30, 2021 and 2020:

### Overview of the Company’s Performance

The second quarter of 2020 began with a degree of hesitation in our markets, as buyers and sellers monitored the durability of the critical infrastructure, including supply chain, transportation and manufacturing. Over the course of that quarter, companies such as ours adapted to social restrictions, gained greater confidence and resumed business activity in a more normalized way. Shifting our focus to 2021, our industry has seen significant improvements in commodity pricing that has been coincident with considerable progress in vaccination campaigns and reductions in social restrictions. In a sense, to date, 2021 has been commonly seen as a year of recovery from the pandemic. Following a comparatively strong first quarter of 2021, the Company has continued that trend into the second quarter of 2021, during which net sales increased by 29 % ($134,610 as compared to $104,555 in second quarter of 2020) and net income increased by 32% ($5,144 as compared to $3,887 in the comparable period of 2020).

On a consolidated basis, domestic sales rose 44% and international sales increased 10%, resulting in an overall net sales improvement of about 29%. Cost of sales increased by 28%, primarily due to the volume growth in sales, the variability in mix of sales and changes in overall factory performance including the new factories acquired as part of the acquisition of the Agrinos Group at the end of 2020. Cost of sales were 61% of sales in both 2021 and 2020. These factors, taken together, yielded a 28% increase in gross profit (to $52,139 from $40,306 in the comparable quarter of 2020). Net cost of our manufacturing activity was impacted by a slow down to accommodate required mechanical integrity inspection activity in Axis, the start-up of the PCNB unit in Los Angeles and the addition of biological fermentation facilities acquired with the Agrinos businesses. Average gross margin percent for the second quarter of 2021 remained level with that of the same period in 2020 at 39% of sales.

Operating expenses on an absolute basis increased by about 28%, as compared to the comparable quarter (to $43,080 from $33,579), and remained flat as a percent of net sales at 32% for the 3-month period ended June 30, 2021, as compared to the same period of 2020. Operating profit for the period rose 33% (to $8,971 from $6,727), driven by a slightly higher concurrent sales increase. During the quarter, interest expense decreased by 20%, in comparison to the same period of the prior year, driven by cash generated over the last year and a slight improvement in the effective interest rate. Income taxes increased by 48%, as a result of both higher pre-tax income and a slightly higher effective tax rate (32% as compared to 29% in the comparable period of 2020). These factors yielded net income for the period of $5,144, which was 32% higher than that of the same quarter in 2020. Details on our financial performance are set forth below.

### RESULTS OF OPERATIONS

### Quarter Ended June 30, 2021 and 2020:

| Net sales: | 2021 | 2020 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| U.S. crop | $62,575 | $44,670 | $17,905 | 40% |
| U.S. non-crop | 21,488 | 13,872 | 7,616 | 55% |
| Total U.S. | 84,063 | 58,542 | 25,521 | 44% |
| International | 50,547 | 46,013 | 4,534 | 10% |
| Total net sales: | $134,610 | $104,555 | $30,055 | 29% |
| Cost of sales: |  |  |  |  |
| U.S. crop | $35,770 | $22,912 | $12,858 | 56% |
| U.S. non-crop | 11,706 | 6,843 | 4,863 | 71% |
| Total U.S. | 47,476 | 29,755 | 17,721 | 60% |
| International | 34,995 | 34,494 | 501 | 1% |
| Total cost of sales: | $82,471 | $64,249 | $18,222 | 28% |
| Gross profit: |  |  |  |  |
| U.S. crop | $26,805 | $21,758 | $5,047 | 23% |
| U.S. non-crop | 9,782 | 7,029 | 2,753 | 39% |
| Total U.S. | 36,587 | 28,787 | 7,800 | 27% |
| International | 15,552 | 11,519 | 4,033 | 35% |
| Total gross profit | $52,139 | $40,306 | $11,833 | 29% |
| Gross margin: |  |  |  |  |
| U.S. crop | 43% | 49% |  |  |
| U.S. non-crop | 46% | 51% |  |  |
| Total U.S. | 44% | 49% |  |  |
| International | 31% | 25% |  |  |
| Total gross margin | 39% | 39% |  |  |

22

Our **domestic crop business** recorded net sales that were over 40% higher than those of the second quarter 2020 ($62,575 as compared to $44,670). Rising crop commodity prices prompted growers and retailers to increase their purchases of crop protection inputs. In corn, sales of our leading soil insecticide Aztec® and our Impact® post emergent herbicide brands drove a 39% year-over-year increase in these key products. Among other granular soil insecticides, Thimet®, used in peanuts and sugar cane, increased by 8% as compared to the prior year. Sales of our soybean products were flat, as compared to the same quarter in 2020. Fueled by renewed potato demand as pandemic restrictions on restaurants and schools eased, sales of our soil fumigants grew significantly. With respect to cotton products, sales of our Bidrin® foliar insecticide doubled during the period with improved weather conditions and higher insect pressure. Similarly, we experienced increased demand for our Folex® harvest defoliant due largely to higher cotton prices and increased harvestable acreage in West Texas. In general, most of our products sold into the U.S. crop sector either equaled or exceeded their sales performance of the second quarter of 2020.

Cost of sales within the domestic crop business increased significantly both as a result of the increased volumes just discussed, a different mix of sales and increased net factory costs. This generated an increase of 23% in gross profit (to $26,805 from $21,758 in the first quarter of 2020).

Within our **domestic non-crop business**, net sales increased by 55% (to $21,488 from $13,872) quarter-over-quarter. Sales of our Dibrom® mosquito adulticide sales grew significantly in the second quarter, influenced by timing shifts in customer procurement, as the distribution channel prepared to respond to the 2021 hurricane and tropical storm season being forecast by National Oceanic and Atmospheric Administration. Our pest strips business sales grew by more than 56%, as consumer and commercial demand improved with the relaxation of pandemic restrictions. In addition, royalty and license fees for our Envance proprietary solutions reflected a steady stream of payments from Proctor & Gamble for the formulations that are used in their Zevo® consumer pest spray brand. We recorded more than a 27% improvement in net sales from our OHP nursery and ornamental business as demand for ornament and decorative plants stayed strong across the U.S.

Cost of sales within the domestic non-crop business grew to $11,706, as compared to $6,843 in the prior quarter. This increase was due largely to volume and mix of sales and increased net factory cost, caused by a slower than expected start-up of our PCNB manufacturing cell at the Los Angeles facility and mechanical integrity inspection activity at the Axis site. Gross profit for domestic non-crop increased by 39% (to $9,782 from $7,029 in 2020).

Net sales of our **international businesses** rose by about 10% during the period (to $50,547 in 2021 from $46,013 in 2020). Newly acquired businesses contributed to this result. With more favorable weather conditions and the addition of our recently acquired AgNova business, we experienced a 3-fold sales increase from our Australian business. The addition of the Agrinos biological products business also contributed incrementally to international sales in China and India. Further, Mexico posted strongly improved sales with stable demand for granular insecticides and very strong demand for our bromacil herbicides, and soil fumigants for use in a number of high-value vegetable crops. While we experienced a decline in European sales of our Mocap and Nemacur granular soil insecticides, as a result of regulatory action last year, in Brazil net sales increased sharply with the recovery of the agricultural sector following the height of the pandemic. Finally, our businesses in Central America reported increases in sales, as AgriCenter successfully overcame supply and logistical difficulties arising from the pandemic.

The cost of sales in our international business was flat, quarter-over-quarter, while gross profit rose by 35% (to $15,552 from $11,519) due in part to a concerted effort to market higher margin products in Central America, greater supply availability of certain herbicide products in Mexico and the addition of biological products from newly acquired businesses.

On a consolidated basis, gross profit for the second quarter of 2021 increased by 29% (to $52,139 from $40,306 in 2020). As mentioned above, despite some increased net factory cost, gross margins remained level at 39% in the second quarter of 2021, as compared to the same period of the prior year.

Operating expenses increased by $9,501 to $43,080 for the three months ended June 30, 2021, as compared to the same period in 2020. The differences in operating expenses by department are as follows:

|  | 2021 | 2020 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $11,611 | $10,031 | $1,580 | 16% |
| General and administrative | 15,264 | 10,515 | 4,749 | 45% |
| Research, product development and regulatory | 6,929 | 6,104 | 825 | 14% |
| Freight, delivery and warehousing | 9,276 | 6,929 | 2,347 | 34% |
|  | $43,080 | $33,579 | $9,501 | 28% |

23

- Selling expenses increased by $1,580 to end at $11,611 for the three months ended June 30, 2021, as compared to the same period of 2020. The main drivers were the costs associated with the activities from the businesses acquired in the last quarter of 2020, increased labor costs related to inflation and some key staff additions. Further, travel costs increased across our global operating subsidiaries as domestic travel restrictions were lifted during the period.
- General and administrative expenses increased by $4,749 to end at $15,264 for the three months ended June 30, 2021, as compared to the same period of 2020. The main drivers were the costs associated with the addition of the entities acquired in the final quarter of 2020, the increase in short-term and long-term incentive compensation of $1,858, reflecting improved financial performance, additional legal expenses of $996 largely arising from the Department of Justice investigation, and an increase in bad debt expenses of $107. Finally, we recorded an expense of $1,014 related to the adjustment to the fair value of contingent consideration associated with an acquisition made in the final quarter of 2020.
- Research, product development costs and regulatory expenses increased by $825 to end at $6,929 for the three months ended June 30, 2021, as compared to the same period of 2020. The main drivers were the addition of new activities associated with acquired entities, general inflation in labor costs including the addition of some key technical headcount and in our product defense and product development costs relating to the commercialization of our SIMPAS delivery system.
- Freight, delivery and warehousing costs for the three months ended June 30, 2021, were $9,276 or 6.9% of sales as compared to $6,929 or 6.6% of sales for the same period in 2020. This change was primarily driven by the mix of product shipped and associated delivery charges, which are up over 500% in some instances during the period.

On April 1, 2020, the Company made a strategic investment in Clean Seed Inc., in the amount of $1,190. During the three months ended June 30, 2021, and 2020, the Company recorded a (decrease) increase in fair value in the amount of $(295) and $24, respectively. These changes in fair value of our investment directly reflect changes in the stock’s quoted market price.

Interest costs net of capitalized interest were $1,013 in the three months ended June 30, 2021, as compared to $1,274 in the same period of 2020. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Three months ended June 30, 2021 Average Debt | Interest Expense | Interest Rate | Three months ended June 30, 2020 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $163,140 | $984 | 2.4% | $185,989 | $1,248 | 2.7% |
| Amortization of deferred loan fees | — | 80 | — | — | 80 | — |
| Amortization of other deferred liabilities | — | (25) | — | — | 3 | — |
| Other interest (income) expense | — | 39 | — | — | 26 | — |
| Subtotal | 163,140 | 1,078 | 2.6% | 185,989 | 1,357 | 2.9% |
| Capitalized interest | — | (65) | — | — | (83) | — |
| Total | $163,140 | $1,013 | 2.5% | $185,989 | $1,274 | 2.7% |

The Company’s average overall debt for the three months ended June 30, 2021 was $163,140, as compared to $185,989 for the three months ended June 30, 2020. Our borrowings in the three months ended June 30, 2021, were lower mainly due to cash generated over the last 12 months, used to pay down debt, partially offset by the acquisition activity over the same period and the associated investment in expanded working capital. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.4% for the three months ended June 30, 2021, as compared to 2.7% in 2020.

Income tax expense increased by $880 to $2,445 for the three months ended June 30, 2021, as compared to $1,565 for the comparable period in 2020. The effective tax rate for the three months ended June 30, 2021, and 2020, was 31.9% and 28.6%, respectively. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The increase in effective tax rate is primarily driven by the mix of our domestic and international income.

Our net income for the three months ended June 30, 2021, was $5,144 or $0.17 per basic and diluted share, as compared to $3,887 or $0.13 per basic and diluted share in the same quarter of 2020.

### Six Months Ended June 30, 2021 and 2020:

### Overview of the Company’s Performance

Within the global agricultural industry, the first six months of 2021 were characterized by greater confidence (having just arisen from the worst of the pandemic) and stronger commodity pricing for row crops. Domestic markets within our industry gained strength during the first quarter and continued that trend into the second. Our international businesses, for the most part, enjoyed similar market trends. All told, the Company’s overall operating results for the first six months of 2021 improved considerably over those of the same period of 2020.

On a consolidated basis, with domestic sales up 30% and international sales up by 17%, overall net sales increased by 25% (to $250,765 from $200,517). Cost of sales were up 26% on an absolute basis but remained flat as a percent of net sales at 61%. Factory performance declined during the first half of 2021, as compared to that of 2020. These factors, taken together, yielded an increase in gross profit, which was up $18,583 or 24% (to $97,270 from $78,687) and remained level when compared to net sales at 39%. In the first half of 2021, while operating expenses rose on an absolute basis by 21%, these costs declined as a percent of net sales to 34% from 35% for the same period of the prior year.

Interest expense declined by 30% as a result of cash generated over the last 12-months, use to pay down debt. Income tax expense increased primarily as a result of stronger financial performance plus an increase in effective tax rate and decreased benefit from discrete items compared to prior year (at 31% as compared to 23% in the prior year). Overall the Company generated increased net income for the period of $8,215 from $4,407 during the first half of the prior year, up 86%. Details on our financial performance are set forth below.

### RESULTS OF OPERATIONS

### Six months ended June 30, 2021, and 2020

| Net sales: | 2021 | 2020 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| U.S. crop | $117,330 | $95,032 | $22,298 | 23% |
| U.S. non-crop | 38,941 | 24,865 | 14,076 | 57% |
| Total U.S. | 156,271 | 119,897 | 36,374 | 30% |
| International | 94,494 | 80,620 | 13,874 | 17% |
| Total net sales: | $250,765 | $200,517 | $50,248 | 25% |
| Cost of sales: |  |  |  |  |
| U.S. crop | $69,254 | $49,029 | $20,225 | 41% |
| U.S. non-crop | 19,776 | 13,117 | 6,659 | 51% |
| Total U.S. | 89,030 | 62,146 | 26,884 | 43% |
| International | 64,465 | 59,684 | 4,781 | 8% |
| Total cost of sales: | $153,495 | $121,830 | $31,665 | 26% |
| Gross profit: |  |  |  |  |
| U.S. crop | $48,076 | $46,003 | $2,073 | 5% |
| U.S. non-crop | 19,165 | 11,748 | 7,417 | 63% |
| Total U.S. | 67,241 | 57,751 | 9,490 | 16% |
| International | 30,029 | 20,936 | 9,093 | 43% |
| Total gross profit | $97,270 | $78,687 | $18,583 | 24% |
| Gross margin: |  |  |  |  |
| U.S. crop | 41% | 48% |  |  |
| U.S. non-crop | 49% | 47% |  |  |
| Total U.S. | 43% | 48% |  |  |
| International | 32% | 26% |  |  |
| Total gross margin | 39% | 39% |  |  |

25

Our **domestic crop business** recorded net sales that were 24% above those of first half of 2020 (to $117,330 from $95,032). Higher crop commodity prices and solid economic recovery alleviated prior concerns about near-term demand and allowed procurement patterns in the domestic market to be elevated as customer consumption increased at every level preparing for the 2021-2022 growing season. In Midwest corn, we posted much higher sales of our key soil insecticides and our post-emergent herbicide Impact, as customers invested to protect their crops from pests such as corn root worm or challenging weeds in order to maximize yield during this time of higher commodity prices. Sales of our cotton products increased significantly, due primarily to higher commodity prices and favorable weather which provided incremental demand for our Folex harvest defoliant in Texas. Soil fumigant sales also increased, fueled by renewed demand in potatoes and other vegetables resulting from the reopening of restaurants and schools. Among our many other products, we saw increased sales in virtually every category, including single digit gains for several of our soil insecticides and double-digit growth for some of our most profitable specialty herbicides and growth regulators.

Cost of sales within the domestic crop business increased 41%, as compared to the first six months of 2020, driven by mix changes and a generally weaker factory performance, including the newly acquired Agrinos biological manufacturing facilities. Gross profit rose by 5% (to $48,076 from $46,003).

Our **domestic non-crop business** recorded a 57% year-over-year increase in net sales (to $38,941 from $24,865). In this category, sales of our Dibrom® mosquito adulticide sales grew significantly, influenced by distribution channel inventory restocking and timing shifts in customer procurement. Demand for commercial pest control products (pest strips, bifenthrin) improved considerably from 2020 pandemic levels. Revenues for our Envance technologies increased significantly when compared to the first half of last year, due primarily to additional license fees and royalties during the first quarter of 2021. Our OHP nursery and ornamental business continued to post increased sales, as demand for homeowner garden and landscape products remained strong throughout the first half of the year. Our GemChem pharmaceutical supply business also grew, benefitting from the rebounding economy.

Cost of sales within the domestic non-crop business increased by 51%, broadly in line with the growth in sales (to $19,776 from $13,117) during the first half of 2021 versus the comparable period in 2020. Gross profit for domestic non-crop increased by 63% (to $19,165 from $11,748 in 2020), consistent with sales growth.

Net sales of our **international businesses** increased by 17% during the first half of 2021 (to $94,494 in 2021 from $80,620 in 2020). Strong results in Mexico and Australia contributed significantly to this success. Mexico posted improved sales with continuing demand for granular insecticides, bromacil herbicides and soil fumigants for use on high-value vegetable crops. In Australia, the integration of recently acquired AgNova with our existing business in that territory drove sales to five-times previous levels. Sales performance was down slightly in Central America resulting from COVID-19 limitations on in-person sales and marketing efforts, and some instances of unfavorable weather in the region earlier this year. While in Europe, sales of our Mocap® insecticide continued to decline during the phase-out of that product following the cancellation of its registration in the EU. In Canada, we experienced a sharp decline in Assure II sales due to intense first half price competition, and in Brazil, net sales increased sharply in the first half, due to a rebound in the agricultural sector following the height of the pandemic.

Cost of sales in our international business increased by 8% (to $64,465 from $59,684 in 2020) primarily driven by volume growth and mix and foreign currency changes. Gross profit for the international businesses increased by 43% (to $30,029 from $20,936) during the period.

On a consolidated basis, gross profit for the six months of 2021 increased by 24% (to $97,270 from $78,687), as a result of improved sales volumes detailed above. Factory performance, however, declined during the first six months of 2021, as compared to the same period of 2020. Gross margin performance, when expressed as a percentage of sales, remained flat at 39%.

Operating expenses increased by $14,400 to $84,524 for the six-months ended June 30, 2021, as compared to the same period in 2020. The differences in operating expenses by department are as follows:

|  | 2021 | 2020 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $22,765 | $20,505 | $2,260 | 11% |
| General and administrative | 31,091 | 23,020 | 8,071 | 35% |
| Research, product development and regulatory | 13,545 | 12,257 | 1,288 | 11% |
| Freight, delivery and warehousing | 17,123 | 14,342 | 2,781 | 19% |
|  | $84,524 | $70,124 | $14,400 | 21% |

- Selling expenses increased by $2,260 to end at $22,765 for the six months ended June 30, 2021, as compared to the same period of 2020. The main drivers were the costs associated with the activities from the businesses acquired in the last quarter of 2020,

increased labor costs related to inflation and some key staff additions. These increased expenses were somewhat offset by the reduction in advertising and promotion costs, the favorable impact of lower foreign currency exchange rates (as they relate to the translation of operating expenses of certain foreign subsidiaries) and decreased travel and entertainment activities across our global operating subsidiaries, as a result of restrictions imposed in response to the COVID-19 pandemic.

- General and administrative expenses increased by $8,071 to end at $31,091 for the six months ended June 30, 2021, as compared to the same period of 2020. The main drivers were the costs associated with the addition of the entities acquired in the final quarter of 2020, the increase in short-term and long-term incentive compensation of $3,060, additional legal expenses of $1,837 largely arising from the Department of Justice investigation, and increased bad debt expenses of $553. Finally, we recorded an expense of $1,014 related to the adjustment to the fair value of contingent consideration associated with an acquisition made in the final quarter of 2020.
- Research, product development costs and regulatory expenses increased by $1,288 to end at $13,545 for the six months ended June 30, 2021, as compared to the same period of 2020. The main drivers were increases in our product defense and product development costs from the recently acquired international businesses.
- Freight, delivery and warehousing costs for the six months ended June 30, 2021 were $17,123 or 6.8% of sales as compared to $14,342 or 7.2% of sales for the same period in 2020. This change reflects increased overall sales offset by a change in the mix of product shipped and associated delivery charges, which are up over 500% in some instances during the period.

During the six months ended June 30, 2021, and 2020, the Company recorded an increase in the fair value of our equity investment in Clean Seed in the amount of $771 and $24, respectively. These changes in fair value of our investment directly reflect changes in the stock’s quoted market price.

During the six months ended June 30, 2021, a Paycheck Protection Program loan assumed on the acquisition of Agrinos in the fourth quarter of 2020 was fully extinguished with the majority of the balance forgiven and recorded as other income in the Company’s Condensed Consolidated Statements of Operations in the amount of $672.

Interest costs net of capitalized interest were $1,959 in the first six months of 2021, as compared to $2,782 in the same period of 2020. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2021 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2020 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $144,324 | $1,843 | 2.6% | $175,475 | $2,744 | 3.1% |
| Amortization of deferred loan fees | — | 161 | — | — | 139 | — |
| Amortization of other deferred liabilities | — | (9) | — | — | 6 | — |
| Other interest (income) expense | — | 89 | — | — | 57 | — |
| Subtotal | 144,324 | 2,084 | 2.9% | 175,475 | 2,946 | 3.4% |
| Capitalized interest | — | (125) | — | — | (164) | — |
| Total | $144,324 | $1,959 | 2.7% | $175,475 | $2,782 | 3.2% |

The Company’s average overall debt for the six months ended June 30, 2021, was $144,324, as compared to $175,475 for the six months ended June 30, 2020. During the period, we continued to focus on our usage of revolving debt, while funding working capital for the newly acquired products and businesses. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.6% for the six months ended June 30, 2021, as compared to 3.1% in 2020.

Income tax expense increased by $2,447 to end at $3,807 for the six months ended June 30, 2021, as compared to income tax expense of $1,360 for the comparable period in 2020. The effective tax rate for the six months ended June 30, 2021, was 31.4% as compared to 23.4% for same period last year. The effective tax rate for the six months ended June 30, 2020, included two discrete income tax benefits. First, the Company assessed its income tax positions to account for the Coronavirus Aid Relief and Economic Security Act (“CARES Act”) which was signed into law on March 27, 2020. A provision of the act modified the amount of interest deduction allowed and therefore reduced the Company’s 2019 Global Intangible Low Tax Income (“GILTI”) inclusion. Second, the Company benefited from the tax impact of the vesting of certain stock grants. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Our net income for the six months ended June 30, 2021 was $8,215 or $0.28 per basic and $0.27 per diluted share, as compared to $4,407 or $0.15 per basic and diluted share in the same period of 2020.

### LIQUIDITY AND CAPITAL RESOURCES

The Company’s operating activities utilized net cash of $18,904 during the six months ended June 30, 2021, as compared to providing net cash of $6,915 during the six months ended June 30, 2020. Included in the $18,904 are net income of $8,215, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $12,732, amortization of deferred loan fees of $162 and provision for bad debts in the amount of $945. Also included are stock-based compensation of $3,598, adjustment to contingent consideration in the amount of $1,014, losses from equity method investment of $87, decrease in deferred income taxes of $353, change in fair value of an equity investment of $771, loan principal and interest forgiveness of $672, net foreign currency adjustments of $147 and adjustment to bargain purchase gain on business acquisition of $121. These together provided net cash inflows of $24,931, as compared to $18,190 for the same period of 2020.

During the six months of 2021, the Company increased working capital by $43,715, as compared to an increase of $11,282 during the same period of the prior year. Included in this change: inventories increased by $11,464 (normal at this point in the season), as compared to $21,706 for the same period of 2020. Deferred revenue decreased by $30,407, as compared to $2,431 in the same period of 2020, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $6,190, as compared to decreased by $12,351 in the same period of 2020. Accounts receivables increased by $25,317, as compared to decreased by $16,421 in the same period of 2020. This is primarily driven by increased group sales and strong international growth. Prepaid expenses increased by $3,696, as compared to $2,297 in the same period of 2020. Income tax receivable decreased by $1,374, as compared to $899 in the prior year. Accrued programs increased by $19,098, as compared to $12,577 in the prior year, which is normal at this point in the growing season. Finally, other payables and accrued expenses increased by $507, as compared to decreased by $2,394 in the prior year.

With regard to our program accrual, the increase (as noted above) primarily reflects our mix of sales and customers in the first six months of 2021, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first six months of 2021, the Company made accruals for programs in the amount of $39,235 and payments in the amount of $20,142. During the first six months of the prior year, the Company made accruals in the amount of $33,336 and made payments in the amount of $20,771.

Cash used for investing activities for the six months ended June 30, 2021, and 2020 was $15,500 and $11,465, respectively. The Company spent $5,075 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure, made a deposit on a product line acquisition of $10,000, intangible assets of $241 and further investment of $184.

During the six months ended June 30, 2021, and 2020, financing activities provided $37,942 and $5,984, respectively. This is principally from the increased borrowings on the Company’s senior credit facility. In the first half of 2021, the Company paid dividends to stockholders amounting to $1,189, as compared to $1,168 in the same period of 2020. In addition, the Company made payments on contingent consideration in the amount of $250, as compared to $1,227 in the same period of 2020.

The Company has a revolving line of credit that is shown as long-term debt in the Condensed Consolidated Balance Sheets at June 30, 2021 and December 31, 2020. These are summarized in the following table:

| Long-term indebtedness ($000's) | June 30, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Revolving line of credit | $149,700 | $107,900 |
| Deferred loan fees | (322) | (458) |
| Net long-term debt | $149,378 | $107,442 |

28

At June 30, 2021, the Company was compliant with all covenants to its then current credit agreement. Also, at June 30, 2021, the Company’s total Funded Debt amounted to $149,700. At that date the Company’s rolling four quarter Consolidated EBITDA (as defined in the Credit Agreement, see Note 10) amounted to $59,030, which results in a leverage ratio of 2.54, as compared to a maximum leverage ratio permitted under the Credit Agreement of 3.5. At June 30, 2021, the Company has the capacity to increase its borrowings by up to $56,906, according to the terms thereof. This compares to an available borrowing capacity of $49,420 as of June 30, 2020. At December 31, 2020, the Company had borrowing capacity of $86,736. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve-month period and proforma basis arising from acquisitions, (2) net borrowings, and (3) the leverage covenant (the TL Ratio).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2020, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2020.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the Condensed Consolidated Financial Statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

## Market risk

As filed, 1,236 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2020 and note 10 to the Condensed Consolidated Financial Statements.

The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.

Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.

## Controls and procedures

As filed, 1,056 characters.

As of June 30, 2021, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2021, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 1,734 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 31, 2021. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors, except for the following:

***The COVID-19 pandemic is creating risk, uncertainty and adverse conditions in many industries both here and abroad.*** The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how the pandemic will impact its customers, business partners, and employees. While the Company did not incur significant disruptions from the COVID-19 pandemic during the six months ended June 30, 2021, the Company is unable to predict the impact that the pandemic will have on its financial condition, results of operations and cash flows due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. There is no guarantee that the Company will be able to operate without material disruption for the duration of the pandemic or that its financial conditions and results of operations will not be materially adversely affected by the pandemic in future quarters.

Filed Aug 10, 2021.
Source: SEC EDGAR, the filing index for accession 0001564590-21-042998. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
